Celldex Therapeutics Is Maintained at Overweight by Morgan Stanley
Ratings actions from Benzinga: GMT) Celldex Therapeutics Price Target Raised to $57.00/Share From $50.00 by Morgan StanleyRatings actions from Benzinga
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Celldex price target raised to $50 from $46 by Morgan Stanley
Morgan Stanley raised its price target on Celldex Therapeutics to $50.00 per share from $46.00. The stock is maintained at Overweight by Morgan Stanley, per Benzinga via TradingView News.